Oncodesign announces the selection of its First-in-Class RIPK2 inhibitor drug candidate for auto-immune and inflammatory diseases 17/12/19 DOWNLOAD
Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP) 24/10/19 DOWNLOAD
Acceleration in growth in the first half of 2019, with sales rising 52% to €14 million 25/07/19 DOWNLOAD
